In:
Thoracic Cancer, Wiley, Vol. 13, No. 22 ( 2022-11), p. 3225-3228
Abstract:
Epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors are standard therapeutic agents for non‐small cell lung cancer (NSCLC) patients with major EGFR mutations such as exon 19 deletions and a L858R mutation, whereas treatment strategies for cases with uncommon EGFR mutations remain to be fully established. Here, we report a long‐term (≥20 years from initial diagnosis) NSCLC survivor carrying EGFR L858R and L747V mutations. The patient received gefitinib monotherapy, systemic chemotherapy/chemoimmunotherapy, and local consolidative therapies for oligometastatic lesions, and responded to afatinib rechallenge with a progression‐free survival of 12 months. The current case suggests that afatinib is effective in NSCLC patients with EGFR L858R and L747V mutations and that a therapeutic approach combining appropriately timed systemic therapies with local consolidative therapies for oligometastatic lesions improves long‐term survival.
Type of Medium:
Online Resource
ISSN:
1759-7706
,
1759-7714
DOI:
10.1111/1759-7714.14678
Language:
English
Publisher:
Wiley
Publication Date:
2022
detail.hit.zdb_id:
2559245-2
Permalink